Previous close | 0.5000 |
Open | 0.5000 |
Bid | 0.0000 |
Ask | 0.9000 |
Strike | 15.00 |
Expiry date | 2024-12-20 |
Day's range | 0.5000 - 0.5000 |
Contract range | N/A |
Volume | |
Open interest | 5 |
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditure Associated with Three-Year Expansion Program Completed -- -- FY 2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedic
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...